JB Chemicals share price rises 70% in a year. Should you Buy, Sell or Hold the stock?
J.B. Chemicals & Pharmaceuticals share price has seen more than 70% gains during last one year. J.B.
Chemicals share is also trading near 52 week highs seen at the start of 2022. This has been led by improving financial performance of J.B. Chemicals.
and earnings outlook has further improved with organic and inorganic measures taken by the J. B. Chemicals.
J.B. Chemicals domestic business revenues have grown 27% CAGR over FY20-23, as per company's presentation. Strong Growth has been led by chronic business growth of J.B.
Chemicals . The chronic business growth of J .B Chemicals for 3 years stood at 23% CAGR (compound annual growth rate) outperforming the Industry's 10% 3 year CAGR. Also Read- Stocks to buy this week: RIL, SBI, Nazara Tech, YES Bank, HCL Tech, IREDA among 12 technical picks; do you own any? In December 2023 , J.B.
Chemicals has also executed a Trade Mark License Agreement with Novartis Innovative Therapies AG, Switzerland for a portfolio of select ophthalmology brands and promotion & distribution agreement with Novartis Healthcare Private Limited, India for the same select ophthalmology brands. The two agreements entered with Novartis are for 10 ophthalmology brands for the Indian market commencing December 2023. The first one allows J.B.
Chemicals to exclusively promote and distribute Novartis’ products for three years . J.B. Chemicals would employ 100 Novartis MRs and expand the team in coming months to ramp up sales, say analysts.
The second one would give J.B. Chemicals trademark licenses for the same brands effective January 2027 for $116million payable on or before December 2026. The deal allows J.B.
Read more on livemint.com
